Background: Increasing evidence suggests that the low-affinity receptor for IgE, CD23, plays an important role in controlling the activity of allergen-specific T cells through IgE-facilitated allergen presentation. Objective: We sought to determine the number of CD23 molecules on immune cells in allergic patients and to investigate whether the number of CD23 molecules on antigen-presenting cells is associated with IgE levels and influences allergen uptake and allergen-specific T-cell activation. Methods: Numbers of CD23 molecules on immune cells of allergic patients were quantified by using flow cytometry with QuantiBRITE beads and compared with total and allergenspecific IgE levels, as well as with allergen-induced immediate skin reactivity. Allergen uptake and allergen-specific T-cell activation in relation to CD23 surface density were determined by using flow cytometry in combination with confocal microscopy and T cells transfected with the T-cell receptor specific for the birch pollen allergen Bet v 1, respectively. Defined IgE-allergen immune complexes were formed with human monoclonal allergen-specific IgE and Bet v 1. Results: In allergic patients the vast majority of CD23 molecules were expressed on naive IgD 1 B cells. The density of CD23 molecules on B cells but not the number of CD23 1 cells correlated with total IgE levels (R S 5 0.53, P 5.03) and allergen-induced skin
IgE is known to have 2 different receptors, the high-affinity receptor FcεRI and the low-affinity receptor CD23 (FcεRII). Cross-linking of FcεRI-bound IgE by allergens mediates degranulation of mast cells and basophils and thus leads to immediate symptoms of allergic disease. 1 In addition, FcεRI is expressed on eosinophils 2 and antigen-presenting cells (APCs; eg, monocytes and dendritic cells) and was shown to be involved in IgE-facilitated allergen presentation to T cells. 3, 4 Interestingly, expression of FcεRI on mast cells, basophils, and even APCs is upregulated by increasing IgE levels, 5, 6 and it was found that omalizumab, an anti-IgE antibody, prevents IgE binding to FcεRI and thereby also downregulates FcεRI expression. 7 Expression of the low-affinity receptor for IgE (CD23), a 45-kDa calcium-binding protein belonging to the family of C-type lectins on various cell types, has been investigated mainly by using cells cultured under various conditions. These studies have shown that CD23 is expressed on B cells, 8 monocytes, 9 T cells, 10 dendritic cells, 11 platelets, 12 and neutrophils. 13 However, expression of the numbers of CD23 molecules on these cell types has not been studied in detail by using ex vivo isolated cells from allergic patients. CD23 has an important function in IgE-facilitated allergen presentation to T cells. 14, 15 In fact, IgE-facilitated antigen presentation strongly activates allergenspecific T cells and secretion of proinflammatory and T H 2-driving cytokines. [14] [15] [16] [17] It has been shown that facilitated antigen presentation can be inhibited with a therapeutic anti-CD23 antibody 18 and by allergen-specific IgG antibodies induced by allergenspecific immunotherapy. 19 An association between improvement of symptoms after specific immunotherapy with a reduction of allergen-IgE binding to CD23 (facilitated antigen binding) on B cells by enhanced levels of blocking IgG antibodies has been demonstrated by using facilitated antigen-binding assays. 20, 21 Despite the importance of CD23 in activating allergen-specific T cells, several aspects of its biology have not been investigated as meticulously as for FcεRI. For example, there are no studies that have investigated the density of the expression of CD23 molecules on ex vivo isolated cells from allergic patients. Studies investigating CD23 mainly focused on the relative number and percentage of cells expressing CD23. [22] [23] [24] [25] [26] [27] [28] [29] Therefore it has also not been studied whether the number of CD23 molecules on the cells is associated with total and allergen-specific IgE levels. Furthermore, there are no systematic studies in defined experimental human model systems that have analyzed whether and how the number of CD23 molecules on APCs has an effect on the magnitude of IgE-facilitated allergen presentation and subsequent T-cell activation.
In the present study we established a new technique for measurement of CD23 receptor molecule numbers on the surfaces of immune cells. We investigated the distribution frequency of CD23 on immune cells in allergic patients and whether and how this parameter is correlated with IgE levels. We also studied whether addition of IgE to PBMC cultures has effects on CD23 expression on B cells. Furthermore, we used CD23 cell lines expressing different numbers of CD23 molecules on their surfaces to study whether and how the density of CD23 molecules on APCs influences IgE-facilitated allergen uptake and allergen-specific T-cell activation.
METHODS Patients
Blood samples from 17 study participants with a positive history suggestive of grass pollen allergy and a positive skin prick test reaction with grass pollen extract were analyzed. Apart from their allergy, none of the subjects had a history of a chronic or current acute disease. Subjects were included in the study during the grass pollen season (ie, during the months of June/July in Vienna). The presence of symptoms of grass pollen allergy (rhinitis, conjunctivitis, and asthma) was recorded at that time. Furthermore, a history of other allergies was obtained. No patients were analyzed who had a contraindication against skin prick testing or were receiving long-term treatment with systemic corticosteroids, immunosuppressive drugs, tranquilizers, or psychoactive drugs. Before the study, patients were not allowed to use oral antihistamines for 3 days and local (in the skin test area) and systemic corticosteroids for 14 days. Blood samples were analyzed in an anonymized manner with approval of the Ethics Committee of the Medical University of Vienna (EK508/2011) after written informed consent was obtained from the patients.
Skin prick tests
Skin test solutions (positive control, timothy grass pollen extract; negative control solution, codeine phosphate; Stallergenes, Antony, France) were applied to the lower arms of patients and were pricked with commercial prick lancets (Allergopharma, Reinbek, Germany). After 20 minutes, the wheal reaction was surrounded with a felt pen and transferred to paper by using adhesive tape. The size of the wheal reactions was measured by using planimetry, as previously described. 30 
Blood samples and total and allergen-specific IgE measurements
Immediately after venipuncture from the antecubital vein, cells from heparinized blood samples were assessed for CD23 expression. Serum was obtained from clotted blood samples by means of centrifugation and stored at 2208C until use. Total IgE and timothy grass pollen-specific IgE levels were measured with the Phadia CAP system (Thermo Fisher, Uppsala, Sweden).
Data analysis
All clinical data (patient history and skin prick test results) were obtained by a clinical investigator and deposited in a database. Measurement of total and specific IgE levels was performed by an independent external laboratory, which was unaware of clinical data and CD23 measurements. Measurement of CD23 levels on different cell types was performed by another independent investigator who was not in contact with the study participants and who was blinded regarding total and specific IgE levels and clinical data (ie, results from skin prick tests and clinical symptoms). After all 3 independent data sets (ie, IgE levels, clinical data, and CD23 measurements) were completed, they were submitted to a database, and correlations were analyzed.
Blood sample preparation and flow cytometry 31 was used for experiments in which high fluorescence intensity was required. Three EBV-transformed, CD23-expressing B-cell lines (high, medium, and low CD23 expression) were generated, as previously described. 32 For each sample of 1 to 2 3 10 5 EBV-transformed B cells, 300 ng of a Bet v 1-specific recombinant mAb with a human IgE heavy chain constant region 33 were incubated with 300 ng of Bet v 1 trimer fluorescently labeled with the Pierce DyLight 488 Labeling Kit (Thermo Scientific, Rockford, Ill), according to the manufacturer's instructions. Alternatively, Bet v 1 trimer 31 was fluorescently labeled with pHrodo Green STP Ester (Life Technologies), according to the manufacturer's instructions. Cells were first blocked with 10% human serum for 20 minutes at 48C. Subsequently, the IgE-allergen complex or allergen alone was added to the cells and incubated for 20 minutes at 48C. Cells were washed with PBS and incubated for 3.5 or 5 hours in RPMI (Gibco, Life Technologies) at 378C and 5% CO 2 . For DyLight 488 labeling, surface fluorescence was removed by means of acid washing immediately after the 20-minute incubation at 48C, as well as after 3.5 and 5 hours of incubation at 378C. For this purpose, cells were exposed to acid wash I (130 mmol/L NaCl, 0.5 mmol/L KCl, and 10 mmol/L lactic acid, pH 3.9) 34 3 times for 5 minutes and additionally to acid wash II (150 mmol/L NaCl and 20 mmol/L HCl, pH 1.7) 35 2 times for 1 minute at room temperature. Surface CD23 was stained by using anti-CD23-PE antibody or matching isotype control. Binding of fluorescently labeled allergen binding (0 hours) or uptake (3.5 and 5 hours) by the cells was measured by means of flow cytometry, as stated above.
CD23 dependency of binding and uptake of IgE-allergen complexes was shown with an anti-CD23 antibody (clone M-L233, BD Biosciences). Anti-CD23 or a matching isotype control (mouse IgG 1 ) was incubated with the cells at a concentration of 15 mg/mL for 20 minutes on ice before incubation with the allergen-IgE complexes.
Uptake of fluorescently (DyLight 488) labeled allergen in confocal microscopy was visualized by using a Zeiss LSM 510 (Zeiss, Oberkochen, Germany) with an oil immersion 360 lens. For this purpose, silhouettes of cells were stained with anti-CD19 (Alexa Fluor 647, clone HIB19; BioLegend, San Diego, Calif) after incubation with allergen-IgE complexes and after acid washing. Cells were then added to adhesion slides (Paul Marienfeld, Lauda-Koenigshofen, Germany), fixed with acetone, and washed twice with PBS, and slides were covered with Fluormount (Sigma-Aldrich, St Louis, Mo). A representative cell sample for each cell line was chosen for depiction.
Cell sorting and T-cell activation assay
An EBV-immortalized B-cell line (HLA-DRB1:0701) was cytometrically sorted for CD23 expression (FACSAria, Becton Dickinson). Briefly, EBV-immortalized B cells were stained with a-human CD23-fluorescein isothiocyanate (TU1; Caltag, Invitrogen-Fisher Scientific) for 30 minutes at 48C, washed once with 13 PBS supplemented with 0.5% wt/vol BSA, and incubated with a-human CD11a (efalizumab, 3 3 10 6 EBV cells, 5-10 mg/mL) for 30 minutes at 48C to prevent homotypic aggregation of the EBV-immortalized B cells. 36 Cells were washed once with 13 PBS/0.5% wt/vol BSA and subsequently sorted for high ( Flow cytometric measurement of MHC and costimulatory molecules
Immunophenotyping of sorted EBV-immortalized B cells was performed with directly conjugated mAbs directed against HLA class II (HLA-DR, L243, and fluorescein isothiocyanate), CD80 (2D10 and PE), CD86 (IT2.2 and allophycocyanin), and CD19 (HIB19 and peridinin-chlorophyll-protein complex), as well as nonbinding isotype control antibodies (BioLegend). Four-color data acquisition was performed on a fluorescence-activated cell sorter FACSCalibur flow cytometer (Becton Dickinson) and analyzed with CellQuest software (Becton Dickinson). MFI data were calculated from the geometric mean of the fluorescent intensity for all positive cells (above isotype control) in the flow cytometric channel used. Only data acquired in the same experiment with the exact same settings were used to compare MFIs.
Stimulation of PBMCs with IgE
PBMCs from blood donors (5 allergic patients with total IgE levels between 200-312 kU/L and 3 nonallergic subjects with total IgE levels <100 kU/L) were isolated by means of Ficoll gradient centrifugation (GE Healthcare, Fairfield, Conn). Aliquots of 1 3 10 6 cells/well were cultivated in 13 RPMI medium (Life Technologies, Grand Island, NY) in 12-well plates together with 1 mg/mL of a purified recombinant human IgE mAb 33 or PBS alone (Life Technologies). All experiments were done in duplicates. CD23 expression on B cells was assessed by means of flow cytometry after 6 days of culture. To this end, 5 3 10 5 total cells were assessed, and B cells were stained with an anti-CD19 antibody (clone HIB19) and an anti-CD23 antibody (clone EBVCS2). Quantification with QuantiBRITE beads was performed, as described above, and results represent means of duplicates with an error of less than 5%.
Statistical analysis
To calculate correlations, we used the Pearson correlation coefficient (R) or the Spearman rank correlation coefficient (R s ), depending on data distribution. Therefore R s was used for correlation of the patient's CD23 levels with IgE and skin sensitivity values because of the skewed distribution of the data. For correlation in in vitro B-cell uptake and T-cell activation experiments, R was used because of the normal data distribution. Coefficients were considered significant at a P value of less than .05.
A paired t test was performed to test the null hypothesis, stating that the mean relative increase of CD23 expression after addition of IgE to PBMCs is zero. Analyses were performed with the software package R, version 3.1.1.
RESULTS

Characterization of patients with grass pollen allergy
Blood samples from 17 patients (9 male and 8 female) with a history of grass pollen allergy (ie, rhinitis, conjunctivitis, and/or asthma during the grass pollen season [May-July]) were analyzed. Clinical and demographic data of the patients are displayed in Table I . All patients had current symptoms of grass pollen allergy (Table I) when skin prick tests were performed and blood samples for flow cytometry and other experiments were obtained. All but 2 patients had a history of other allergies. Total IgE levels ranged between 33 and 10,856 kU/L (median, 462 kU/L), whereas IgE levels specific for timothy grass pollen ranged between 1.1 and 1,204 kU of antigen/L (median, 33 kU of antigen/L). All patients had positive skin prick test reactions to grass pollen extract (12.6-238.7 mm 2 ; median, 61 mm 2 ).
CD23 was expressed mainly on naive IgD 1 B cells in patients with grass pollen allergy When CD23 expression was determined on blood cells from patients with symptoms of grass pollen allergy, we found that the receptor was expressed almost exclusively on B cells. Table II shows that 49.8% of patients' B cells on average expressed CD23 molecules, whereas in most patients only a few monocytes (mean, 1.38%), NK cells (mean, 0.57%), or dendritic cells (mean, 0.43%) were CD23 1 (Table II) . Next, we investigated the CD23 receptor density on the CD23 1 cell populations (Table III) . We found a high density of CD23 molecules expressed on B cells (2168-6719 molecules per cell; mean, 3968 molecules per cell), whereas it was possible to calculate the number of CD23 molecules on monocytes in only 6 of the 17 patients, and the density was lower than on B cells (ie, 388-1465 molecules per cell; mean, 1089 molecules per cell).
To characterize the CD23 1 and CD23 2 populations of B cells, we stained blood cells of 3 patients (patients 8, 11, and 17) with antibodies specific for CD19, CD23, IgD, and CD27 Average numbers of CD23 molecules per CD23 1 B cell and monocyte and concentrations of soluble CD23 in patients' sera (in nanograms per milliliter) were measured in the blood of the 17 patients with grass pollen allergy (Table I) . ND, Numbers of CD23 molecules could not be calculated when less than 20 of the monocytes among the analyzed cells were positive for CD23.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 (see Table E1 in this article's Online Repository at www. jacionline.org). On average, 65.1% of B cells were CD23 1 in these patients. The majority of the CD23 1 cells were also positive for IgD and negative for the memory marker CD27 (naive B cells: mean, 89.2%; see Table E1 ). Only 0.5% of the CD23 
CD27
1 cells, see Table E1 ). The flow cytometric charts of 1 representative patient (patient 11, Table I ) are displayed in Fig E1 in this article' s Online Repository at www.jacionline.org.
Total IgE levels are correlated with numbers of CD23 molecules on B cells
In our group of 17 patients with grass pollen allergy, we found a significant correlation between the density of CD23 on CD23 1 B cells (Table III) and total serum IgE levels (R S 5 0.53, P 5 .03; Fig 1, A) . A pilot experiment showed that addition of purified monoclonal human IgE to cultured PBMCs resulted in a significant increase (mean, 8.5%; P 5 .04) of CD23 expression on B cells, suggesting that IgE can upregulate CD23 expression (see Fig E2 in this article' s Online Repository at www.jacionline.org).
Furthermore, grass pollen-specific serum IgE levels were also linked to the number of CD23 molecules on B cells (R S 5 0.46, P 5.07; Fig 1, B) . We also found a significant correlation between the molecule density of CD23 on B cells (Table III) and the size of skin prick test reactions to grass pollen extract (R S 5 0.63, P 5 .008; Fig 1, C) . Additionally, skin prick test reaction size correlated significantly with grass pollen-specific serum IgE levels (R S 5 0.54, P 5 .03, data not shown). Because only 6 patients showed substantial CD23 expression on monocytes, we did not correlate the number of CD23 molecules on monocytes with respective IgE and skin prick test data.
Neither CD23
1 B-cell numbers nor soluble CD23 levels are correlated with total and specific IgE levels or skin sensitivity
Fig 1 shows correlations of percentages of CD23
1 B cells with total and allergen-specific IgE levels, as well as with grass pollen-specific wheal reactions. In fact, neither total serum IgE levels (R S 5 0.34, P 5 .19; Fig 1, D) nor grass pollen-specific serum IgE levels (R S 5 0.34, P 5 .19; Fig 1, E) correlated with the number of CD23 1 B cells. We also did not find a statistically significant correlation between the percentage of CD23 1 B cells with skin prick test reactivity to grass pollen (R S 5 0.42, P 5 .09; Fig 1, F) .
Also, we analyzed levels of soluble CD23 in sera of the 17 patients (Table III) . However, soluble CD23 serum levels did not correlate with patients' total IgE levels (R S 5 20.12, P 5.66), grass pollen-specific IgE levels (R S 5 20.33, P 5 .19), or grass pollenspecific wheal reactions (R S 5 20.06, P 5 .81, data not shown). Total IgE levels (Fig 1, A and D) , timothy grass pollen-specific IgE levels (Fig 1, B and E) , or sizes of grass pollen-induced wheal reactions (Fig 1, C and F) are plotted on the x-axis. *P values of less than .05. **P values of less than .01. . Cells stained with anti-CD19 are shown in pink, whereas allergen (Bet v 1 trimer) was labeled in green with DyLight 488, preincubated with allergen-specific IgE, and then exposed to the cells. The pictures marked overlay show an overlay of anti-CD19 and allergen staining. B and C, Binding (Fig 2, B) and uptake (Fig 2, C) of a fluorescent allergen-IgE complex by CD23-expressing EBV-transformed B-cell lines (I, II, and III) shown by using flow cytometry. CD23 expression was measured before and after 3.5 hours of incubation with IgE-allergen complexes. Different symbols (circles, I; squares, II: and triangles, III) represent the 3 different B-cell lines. Four independent experiments performed on 4 different study days are displayed. Each data point represents the mean of triplicate experiments done on the same study day. Background fluorescence measured after incubation with allergen alone was subtracted. Dotted lines, Trend lines of correlations. D and E, Binding (Fig 2, D) and uptake (Fig 2, E) of allergen-IgE complexes was blocked by an anti-CD23 antibody but not by the matching isotype control (IgG 1 ). Solid triangles represent blocking by anti-CD23, and open circles show cells incubated with the isotype control.
IgE-facilitated allergen uptake is dependent on CD23 density on B lymphocytes
We used 3 different CD23-expressing EBV-transformed B-cell clones to investigate the possible dependence of IgE-facilitated allergen uptake into B cells on CD23 density. Cell line I had an average number of 3 3 10 5 CD23 molecules per cell, cell line II expressed 1.2 3 10 5 CD23 molecules per cell on average, and cell line III expressed 5 3 10 4 molecules per cell on average (Fig 2) . In a first set of experiments, we measured and compared uptake of the complexes into the different cell lines after removal of bound surface molecules by means of acid washing by incubating the cells with fluorescently labeled allergen-IgE complexes. Allergen uptake into different cell lines was studied by using confocal microscopy, and CD19 1 cells were stained (Fig 2, A) . We found that staining of allergen-IgE immune complexes was more intensive on the cell lines expressing high levels of CD23 molecules (ie, cell lines I and II) compared with the cell line expressing fewer CD23 molecules (ie, cell line III; Fig 2, A) . Cells had been stripped with an acidic wash after incubation with the fluorescently labeled IgE-allergen complexes, followed by anti-CD19 staining. Under these conditions, CD19 stained the silhouette of the sections, whereas labeled allergen appeared intracellularly, indicating that the allergen had been taken up. No allergen staining was observed with any of the 3 CD23-expressing cell lines when allergen-specific IgE was omitted (data not shown).
The findings of the confocal staining experiments were corroborated by a second set of experiments in which allergenIgE binding to the cell surface (Fig 2, B) and uptake into cells (Fig 2, C) were studied by using flow cytometry. In these experiments we found that there was a significant correlation (R 5 0.7, P 5 .01) between the number of CD23 molecules on the cells and binding of the allergen-IgE complexes after 20 minutes of incubation at 48C (Fig 2, B) . An almost linear and striking correlation (R 5 0.98, P 5 .000; Fig 2, C) was found between the uptake of allergen after 3.5 hours of incubation at 378C and the surface density of CD23 molecules on these cells. Both binding and uptake of allergen-IgE complexes could be blocked by an anti-CD23 antibody (Fig 2, D and E) , and both complex binding and uptake were unaffected if a matching isotype control was used instead (Fig 2, D and E) . Our experiments demonstrate the causal dependency of allergen uptake and T-cell activation on IgE-facilitated allergen presentation through CD23. In these experiments the extent of IgE-facilitated allergen uptake was correlated with the surface density of CD23.
To further confirm that allergen-specific signals measured by using flow cytometry were derived only from intracellular compartments and did not represent remaining allergen residing on the cell surface, we repeated the uptake experiment using allergen labeled with the pH-sensitive pHrodo Green, which only emits fluorescence after uptake into endolysosomal compartments because of acidic pH. Again, the measured uptake of allergen significantly correlated with the CD23 surface density (R 5 0.97, P 5 .000, data not shown).
Density of CD23 on the surfaces of B cells determines activation of allergen-specific T cells by IgE-facilitated allergen presentation
Next, we measured whether the density of CD23 on antigen-presenting B cells that had been loaded with IgE-allergen complexes influences the activation of MHCmatched Bet v 1-specific T cells, which expressed a single Bet v 1-specific T-cell receptor. For this purpose, we sorted EBV-transformed B cells into 3 different subpopulations according to their CD23 expression levels (high, intermediate, or low expression), incubated them with equal amounts of Bet v 1-IgE complexes, and measured Bet v 1-specific T-cell activation (Fig 3) . Our experiments showed that T-cell activation was directly dependent on the CD23 surface density of cocultured B cells when incubated together with allergen-IgE complexes (Fig 3, A and B) . Initial CD23 expression on B cells was correlated with subsequent T-cell activation (R 5 0.94, P 5 .000; Fig 3, A) . No relevant T-cell activation was observed when an unrelated allergen (Art v 1) or Bet v 1 without Bet v 1-specific IgE was used for stimulation (Fig 3, B) , and IgE-facilitated T-cell activation could be blocked by an anti-CD23 antibody (Fig 3, C) . In addition to CD23, we also measured MHC class II, CD80, and CD86 expression on sorted B cells. We found some differences in expression of the costimulatory molecules CD80 and CD86. However, there was no difference regarding MHC class II expression in CD23-high and CD23-intermediate cell populations, although T-cell activation was different (see Table  E2 in this article's Online Repository at www.jacionline.org).
DISCUSSION
Several studies performed in patients during allergen-specific immunotherapy have provided evidence that CD23, the lowaffinity receptor for IgE, has an important role in controlling allergen-specific T-cell activation through IgE-facilitated allergen presentation. [19] [20] [21] 39 To investigate the number of CD23 molecules on immune cells of allergic patients, we developed a flow cytometry-based assay using QuantiBRITE beads. Using this assay, we found that CD23 is expressed primarily on naive IgD 1 B cells in the blood of allergic patients and only in negligible numbers on other immune cells.
In fact, CD23 was present on other APCs, such as dendritic cells or monocytes; however, either only a few of these cells were CD23 1 , or expression levels were very low, or both (Table II) . Therefore it was not possible to calculate reliable CD23 expression on their cell surfaces. We must thus assume that mainly B cells play a role in IgE-facilitated allergen presentation through CD23. Interestingly, the number of CD23 molecules per cell and not the percentage of CD23 1 cells was correlated with total IgE levels and allergen-induced immediate type skin reactions and was associated with allergen-specific IgE levels. Pilot experiments even suggested that addition of highly purified human monoclonal IgE might upregulate CD23 expression on B cells in cultured PBMCs from allergic and nonallergic subjects. Thus the surface expression of CD23 seems to follow the rules that guide the expression of the high-affinity receptor for IgE (FcεRI), which was shown to depend on IgE levels 5 and to be regulated directly by IgE binding. 40 In fact, it has also been shown that an anti-IgE antibody (omalizumab), which prevents binding of IgE to FcεRI by shielding IgE binding to the receptor, can downregulate FcεRI expression on basophils, mast cells, and APCs. 7 Next, we were interested in whether the surface density of CD23 on B cells might have an influence on IgE-facilitated allergen uptake and subsequent allergen-specific T-cell proliferation. To study this question, we used defined model systems. We used the purified major birch allergen Bet v 1, a human Bet v 1-specific IgE mAb, T cells transfected with a Bet v 1-specific T-cell receptor, and MHC-matched, EBV-transformed B cells, which were characterized regarding the numbers of CD23 molecules on their surface. The experiments performed showed that allergen uptake by IgE-facilitated allergen presentation was significantly correlated with the numbers of CD23 molecules on the surfaces of APCs and depended on the presence of allergenspecific IgE. It was causally related to the ability of IgE to bind to CD23 because it could be blocked with an anti-CD23 antibody. Furthermore, the strongest T-cell activation was observed when APCs expressing high CD23 levels were used for IgE-facilitated allergen presentation, and we found a significant correlation (P 5 .000) between CD23 levels on B cells and T-cell activation. Taken together, our findings suggest that high levels of allergenspecific IgE upregulate the surface density expression of CD23 on B cells in allergic patients, which might then lead to enhanced IgE-facilitated allergen presentation and activation of allergenspecific T cells. This possible interplay between IgE levels, CD23 surface density on B cells as APCs, and allergen-specific T-cell activation might open possibilities to control T cell-mediated allergic inflammation caused by IgE-facilitated allergen presentation by several nondirectly T cell-or cytokine-targeting approaches and nonpharmacologic strategies. For example, it can be considered to block the CD23-binding site on IgE with anti-IgE antibodies, as has been suggested earlier, 17, 41 to suppress allergen-specific T-cell activation. In this context it was found that omalizumab indeed suppressed markers of T-cell activation when administered to patients with atopic dermatitis. 42 Another possibility would be to block binding of IgE to CD23, such as with therapeutic anti-CD23 antibodies or CD23 variants. 43 In this context it was found that lumiliximab, an anti-CD23 antibody, suppressed allergen-specific T-cell activation in vitro. 18 Also, other ''humoral'' approaches, which primarily focus on IgE production, 44 and interference of the IgE-allergen interaction (eg, passive immunization with blocking allergen-specific IgG 45 ) might have an influence on T cell-mediated allergic inflammation.
In summary, our study suggests that IgE might play a role in the upregulation of CD23 on B cells and demonstrates that the surface density of CD23 on B cells determines allergen uptake and subsequent T-cell activation. These findings conceivably have implications for the treatment of allergic diseases. J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1
